{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:38:56Z","timestamp":1792136336705,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126754","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T17:03:34Z","timestamp":1738083814000},"page":"126754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan"],"prefix":"10.1016","volume":"49","author":[{"given":"Suminobu","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morikuni","family":"Tobita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10224","key":"10.1016\/j.vaccine.2025.126754_bb0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126754_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12879-022-07973-4","article-title":"COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review","volume":"23","author":"Agustin","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126754_bb0015","series-title":"WHO director-General's opening remarks at the media briefing on COVID-19","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126754_bb0020","series-title":"COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide: World Health Organization","author":"R&D Blueprint WHO. DRAFT landscape of COVID-19 candidate vaccines \u2013 2 December","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126754_bb0030","author":"Agreement with AstraZeneca K.K."},{"key":"10.1016\/j.vaccine.2025.126754_bb0040","year":"2020","journal-title":"The 203rd extraordinary session of the National Diet, Ministry of Health, Labour and Welfare"},{"issue":"27","key":"10.1016\/j.vaccine.2025.126754_bb0045","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126754_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10267","key":"10.1016\/j.vaccine.2025.126754_bb0055","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126754_bb0060","year":"2021","journal-title":"Ministry of Health, Labour and Welfare"},{"issue":"22","key":"10.1016\/j.vaccine.2025.126754_bb0065","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2025.126754_bb0070","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126754_bb0075","author":"U.S. DHHS Food and Drug Administration CfBEaR"},{"issue":"15","key":"10.1016\/j.vaccine.2025.126754_bb0080","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: revision of the Brighton collaboration case definition","volume":"41","author":"Gold","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126754_bb0085","doi-asserted-by":"crossref","first-page":"2323853","DOI":"10.1080\/21645515.2024.2323853","article-title":"Factors influencing adverse events following COVID-19 vaccination","volume":"20","author":"Villanueva","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.vaccine.2025.126754_bb0090","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1016\/j.vaccine.2023.06.069","article-title":"Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens","volume":"41","author":"Torp Hansen","year":"2023","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126754_bb0095","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/vaccines10122017","article-title":"Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations","volume":"10","author":"Salter","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126754_bb0100","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1080\/21645515.2021.1985356","article-title":"Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers","volume":"17","author":"Filippatos","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126754_bb0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/14760584.2024.2315089","article-title":"Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis","volume":"23","author":"San Francisco Ramos","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.126754_bb0110","article-title":"Safety and immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in individuals \u226512 years old: a phase 2\/3 trial","volume":"12(2):118","author":"Gayed","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126754_bb0115","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","article-title":"Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines","volume":"230","author":"Chalkias","year":"2024","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126754_bb0120","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/14760584.2022.2093722","article-title":"Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study","volume":"21","author":"Naito","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126754_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2017.11.017","article-title":"Anxiety-related adverse events following immunization (AEFI): a systematic review of published clusters of illness","volume":"36","author":"Loharikar","year":"2018","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126754_bb0130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.15585\/mmwr.mm7018e3","article-title":"Anxiety-related adverse event clusters after Janssen COVID-19 vaccination - five U.S. mass vaccination sites, April 2021","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126754_bb0135","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10875-022-01350-1","article-title":"Anaphylaxis to SARS-CoV-2 vaccines in the setting of a nationwide passive epidemiological surveillance program","volume":"42","author":"Toledo-Salinas","year":"2022","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126754_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-051254","article-title":"The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada","volume":"12","author":"Bettinger","year":"2022","journal-title":"BMJ Open"},{"issue":"13","key":"10.1016\/j.vaccine.2025.126754_bb0145","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126754_bb0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/ijd.16336","article-title":"Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers","volume":"61","author":"Ruiz-Villaverde","year":"2022","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126754_bb0155","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2025.126754_bb0160","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126754_bb0165","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S2468-1253(22)00005-X","article-title":"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study","volume":"7","author":"Alexander","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2025.126754_bb0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijid.2021.07.052","article-title":"Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia","volume":"110","author":"Al Bahrani","year":"2021","journal-title":"Int J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:18:38Z","timestamp":1741346318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S0264410X25000519"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126754","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126754"}}